Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (141-150 of 217) with videos related to

Pageof 22
Sort By:
Hemasphere|August 23, 2021
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSabine Khalife-Hachem, Khalil Saleh, Florence Pasquier, et al.
Gynecologic Oncology|July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
BMC Biology|October 8, 2024
Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor typesChiara Maria Lavinia Loeffler, Omar S M El Nahhas, Hannah Sophie Muti, et al.
Plos One|October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPaul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Cell Reports. Medicine|December 31, 2025
zAvatar-test-A functional precision model to personalize ovarian cancer treatments: Results from a co-clinical studyMarta F Estrada, Filipa Amorim, Filipa Ferreira da Silva, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2022
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trialLisa Vermij, Alicia Léon-Castillo, Naveena Singh, et al.
British Journal of Cancer|April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor eraBenoit You, Lilian Van Wagensveld, Michel Tod, et al.
Pageof 22

Showing results (141-150 of 217) with videos related to

Sort By:
Pageof 22
Hemasphere|August 23, 2021
Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast CancersSabine Khalife-Hachem, Khalil Saleh, Florence Pasquier, et al.
Gynecologic Oncology|July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
BMC Biology|October 8, 2024
Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor typesChiara Maria Lavinia Loeffler, Omar S M El Nahhas, Hannah Sophie Muti, et al.
Plos One|October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPaul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2024
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancerAlejandro Perez-Fidalgo, Barbara Schmalfeldt, Angela George, et al.
Cell Reports. Medicine|December 31, 2025
zAvatar-test-A functional precision model to personalize ovarian cancer treatments: Results from a co-clinical studyMarta F Estrada, Filipa Amorim, Filipa Ferreira da Silva, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 25, 2022
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trialLisa Vermij, Alicia Léon-Castillo, Naveena Singh, et al.
British Journal of Cancer|April 1, 2022
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor eraBenoit You, Lilian Van Wagensveld, Michel Tod, et al.
Pageof 22